Summit Therapeutics Inc.
SMMTDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Nov 1, 2026
24wMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
AK112 Injection
Non-Squamous Non-small Cell Lung Cancer
Ridinilazole
Clostridioides Difficile Infection
Drug: Ivonescimab Injection
Metastatic Colorectal Cancer (CRC)
Pembrolizumab Injection
Non-Small Cell Lung Cancer
Ivonescimab Injection
Non-Small Cell Lung Cancer
Fidaxomicin
Clostridium Difficile Infection
SMT19969
Clostridium Difficile Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AK112 Injection | Phase 3 | Non-Squamous Non-small Cell Lung Cancer | - | - |
Ridinilazole | Phase 3 | Clostridioides Difficile Infection | - | - |
Drug: Ivonescimab Injection | Phase 3 | Metastatic Colorectal Cancer (CRC) | - | - |
Pembrolizumab Injection | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Ivonescimab Injection | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Fidaxomicin | Phase 2 | Clostridium Difficile Infection | - | - |
SMT19969 | Phase 2 | Clostridium Difficile Infection | - | - |